Publication: Association of Cognitive Impairment and Peripheral Inflammation in Methamphetamine-dependent Patients: A Cross-sectional Study on Neuroinflammatory Markers TNF-α and IL-6
2
0
Issued Date
2025-01-01
Resource Type
ISSN
17381088
eISSN
20934327
Scopus ID
2-s2.0-105003457318
Journal Title
Clinical Psychopharmacology and Neuroscience
Volume
23
Issue
2
Start Page
234
End Page
245
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Psychopharmacology and Neuroscience Vol.23 No.2 (2025) , 234-245
Suggested Citation
Permpoonputtana K., Namyen J., Buntup D., Boontem P., Nopparat C., Govitrapong P. Association of Cognitive Impairment and Peripheral Inflammation in Methamphetamine-dependent Patients: A Cross-sectional Study on Neuroinflammatory Markers TNF-α and IL-6. Clinical Psychopharmacology and Neuroscience Vol.23 No.2 (2025) , 234-245. 245. doi:10.9758/cpn.24.1236 Retrieved from: https://hdl.handle.net/20.500.14740/20454
Corresponding Author(s)
Other Contributor(s)
Abstract
Objective: To investigate the cognitive impairment and peripheral inflammation induced by methamphetamine (METH) and their association in METH abusers. Methods: The cross-sectional study included 100 METH-dependent patients and 100 healthy controls. Cognitive screening was conducted using the Thai version of the Montreal Cognitive Assessment (MoCA-T). Thirty normal controls and 30 METH-dependent patients were randomly selected for blood collection to measure inflammatory markers, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, using a quantitative enzyme-linked immunosorbent assay method. Results: METH-dependent patients had significantly poorer MoCA-T scores and higher levels of blood inflammatory markers compared to healthy controls. Demographic characteristics, METH use patterns, and proinflammatory cytokines were associated with cognitive impairment. The MoCA-T score was negatively associated with plasma TNF-α and IL-6 levels. Conclusion: METH-associated cognitive decline is correlated with elevated plasma levels of TNF-α and IL-6 cytokines, indicating the involvement of specific neuroinflammatory pathways in neurocognitive dysfunction. These insights could pave the way for novel therapeutic strategies aimed at mitigating neuroinflammation, potentially improving outcomes for individuals with METH addiction.